Core Viewpoint - A securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. on behalf of investors who purchased its common stock during the February 8, 2024 IPO, with a lead plaintiff deadline set for February 7, 2025 [1]. Group 1: Allegations Against Kyverna - The complaint alleges that Kyverna's IPO prospectus and registration statements contained materially false and misleading statements regarding the company's business, operations, and prospects [2]. - Specifically, it is claimed that Kyverna failed to disclose adverse data related to one of its clinical trials at the time of the IPO [2]. Group 2: Lead Plaintiff Process - Investors in Kyverna have until February 7, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3]. - The lead plaintiff will act on behalf of all class members in directing the litigation and is typically the investor or small group of investors with the largest financial interest [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions in state and federal courts and has a reputation for recovering billions for victims of fraud and corporate misconduct [4].

NEW YORK, Jan. 27, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public offering conducted on February 8, 2024 (the "IPO"), of the important February 7, 2025 lead plaintiff deadline.So what: If you purchased Kyverna common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.W ...

NEW YORK, Jan. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=124866&from=4CLASS PERIOD: T ...

SAN DIEGO, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) and certain of the Company's senior executives and directors who signed the Registration Statement, effective February 7, 2024, issued in connection with the Company's initial public offering ("IPO"). Kyverna is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. For mo ...

Core Viewpoint - A class action securities lawsuit has been filed against Kyverna Therapeutics, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's February 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Kyverna Therapeutics, Inc. [2] - The complaint alleges that false statements and omissions were made regarding the IPO strategy, terms, and disclosures in the Offering Documents [3]. - The underwriter defendants are accused of being aware of Kyverna's undisclosed issues due to constant communications with the company's management and legal representatives [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until February 7, 2025, to request appointment as lead plaintiff [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kyverna To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities investing Kyverna common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 8, 2024 (the "IPO" or "Offering") and would like to discuss your legal rights, call Faruqi & Faruqi partner ...

Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of growth EMERYVILLE, Calif., Jan. 21, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment of Naji Gehchan, M.D., MBA, to Chief Medical and Developmen ...

Core Viewpoint - Kyverna Therapeutics, Inc. is facing a lawsuit for alleged violations of securities laws, which may impact its financial standing and investor confidence [1] Company Summary - The lawsuit is being pursued by Levi & Korsinsky, and affected parties are encouraged to contact the firm before February 7, 2025, to discuss their rights [1]

Kyverna Therapeutics, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm ...

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX ...